Vaccines as a remedy for antimicrobial resistant bacterial infections

Project Information

vAMRes

Grant agreement ID: 787552

DOI 10.3030/787552

Project closed

EC signature date 4 September 2018

Start date 1 November 2018

End date 31 October 2023

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost € 2 432 500,00

EU contribution € 2 432 500,00

Coordinated by

FONDAZIONE TOSCANA LIFE SCIENCES
Italy

Publications

Peer reviewed articles (20)

SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly

Author(s): Onnis, A. et al.
Published in: Journal of Experimental Medicine 220, e20220906, Issue e20220906, 2022, ISSN 0022-1007
Publisher: Rockefeller University Press
DOI: 10.1084/jem.20220906

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

Author(s): Torres Jonathan, L. et al.
Published in: Proceedings of the National Academy of Sciences 119, 2022, ISSN 0027-8424
Publisher: National Academy of Sciences
DOI: 10.1073/pnas.2120976119

Antimicrobial Resistance: A Tale of Nasty Enemies and Powerful Weapons

Author(s): Fabiola Vacca, Dario Cardamone, Marco Troisi, Claudia Sala, Rino Rappuoli
Published in: Frontiers for Young Minds, Issue 8, 2020, ISSN 2296-6846
Publisher: Frontiers Media S.A.
DOI: 10.3389/frym.2020.554493

Antibodies, epicenter of SARS-CoV-2 immunology

Author(s): Simone Pecetta, Mariagrazia Pizza, Claudia Sala, Emanuele Andreano, Piero Pileri, Marco Troisi, Elisa Pantano, Noemi Manganaro, Rino Rappuoli
Published in: Cell Death & Differentiation, Issue 28/2, 2021, Page(s) 821-824, ISSN 1350-9047
Publisher: Nature Publishing Group
DOI: 10.1038/s41418-020-00711-w

Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants

Author(s): Andreano, E. et al.
Published in: Nature 600, pages530–535 (2021), Issue Nature 600, pages530–535, 2021, ISSN 0028-0836
Publisher: Nature Publishing Group
DOI: 10.1038/s41586-021-04117-7

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

Author(s): Emanuele Andreano, Emanuele Nicastri, Ida Paciello, Piero Pileri, Noemi Manganaro, Giulia Piccini, Alessandro Manenti, Elisa Pantano, Anna Kabanova, Marco Troisi, Fabiola Vacca, Dario Cardamone, Concetta De Santi, Jonathan L. Torres, Gabriel Ozorowski, Linda Benincasa, Hyesun Jang, Cecilia Di Genova, Lorenzo Depau, Jlenia Brunetti, Chiara Agrati, Maria Rosaria Capobianchi, Concetta Castilletti, Ar
Published in: Cell, Issue 184/7, 2021, Page(s) 1821-1835.e16, ISSN 0092-8674
Publisher: Cell Press
DOI: 10.1016/j.cell.2021.02.035

SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies

Author(s): Andreano, E. & Rappuoli, R.
Published in: Nature Medicine 27, 759-761, Issue Nature Medicine 27, 759-761, 2021, ISSN 1078-8956
Publisher: Nature Publishing Group
DOI: 10.1038/s41591-021-01347-0

A new dawn for monoclonal antibodies against antimicrobial resistant bacteria

Author(s): Troisi, M. et al.
Published in: Frontiers in Microbiology 13, Issue Frontiers in Microbiology 13, 2022, ISSN 1664-302X
Publisher: Frontiers Media
DOI: 10.3389/fmicb.2022.1080059

Production of two SARS-CoV-2 neutralizing antibodies with different potencies in Nicotiana benthamiana

Author(s): Frigerio, R. et al.
Published in: Frontiers in Plant Science 13, Issue Frontiers in Plant Science 13, 2022, ISSN 1664-462X
Publisher: Frontiers Media S. A.
DOI: 10.3389/fpls.2022.956741

B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response

Author(s): Andreano, E. et al.
Published in: Nature Communications, Issue 14, Article number: 53 (2023), 2023, ISSN 2041-1723
Publisher: Nature Publishing Group
DOI: 10.1038/s41467-022-35781-6

High-throughput bactericidal assays for monoclonal antibody screening against antimicrobial resistant Neisseria gonorrhoeae

Author(s): S. Stazzoni et al.
Published in: Front. Microbiol. Sec. Antimicrobials, Resistance and Chemotherapy, Issue Front. Microbiol., Sec. Antimicrobials, Resistance and Chemotherapy Volume 14 – 2023, 2023, ISSN 1664-302X
Publisher: Frontiers Media
DOI: 10.3389/fmicb.2023.1243427

Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection

Author(s): Lanini, S. et al.
Published in: Nature Communications 13, 2263, 2022, ISSN 2041-1723
Publisher: Nature Publishing Group
DOI: 10.1038/s41467-022-29909-x

Vaccines as remedy for antimicrobial resistance and emerging infections

Author(s): Marco Troisi, Emanuele Andreano, Claudia Sala, Anna Kabanova, Rino Rappuoli
Published in: Current Opinion in Immunology, Issue 65, 2020, Page(s) 102-106, ISSN 0952-7915
Publisher: Elsevier BV
DOI: 10.1016/j.coi.2020.09.003

Immunodominant antibody germlines in COVID-19

Author(s): Andreano, E. & Rappuoli, R.
Published in: Journal of Experimental Medicine 218, Issue Journal of Experimental Medicine 218, 2021, ISSN 0022-1007
Publisher: Rockefeller University Press
DOI: 10.1084/jem.20210281

Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections

Author(s): Pardis Mokhtary, Zeinab Pourhashem, Akram Abouei Mehrizi, Claudia Sala, Rino Rappuoli
Published in: Biomedicines. 2022 Aug 2;10(8):1861, Issue Biomedicines. 2022 Aug 2;10(8):1861, 2022, ISSN 0753-3322
Publisher: Elsevier Masson
DOI: 10.3390/biomedicines10081861

Monoclonal Antibodies for Bacterial Pathogens: Mechanisms of Action and Engineering Approaches for Enhanced Effector Functions

Author(s): Fabiola Vacca, Claudia Sala, Rino Rappuoli
Published in: Biomedicines 30;10(9):2126, Issue Biomedicines 30;10(9):2126, 2022, ISSN 0753-3322
Publisher: Elsevier Masson
DOI: 10.3390/biomedicines10092126

SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma

Author(s): Emanuele Andreano, Giulia Piccini, Danilo Licastro, Lorenzo Casalino, Nicole V. Johnson, Ida Paciello, Simeone Dal Monego, Elisa Pantano, Noemi Manganaro, Alessandro Manenti, Rachele Manna, Elisa Casa, Inesa Hyseni, Linda Benincasa, Emanuele Montomoli, Rommie E. Amaro, Jason S. McLellan, Rino Rappuoli
Published in: Proceedings of the National Academy of Sciences, Issue 118/36, 2021, Page(s) e2103154118, ISSN 0027-8424
Publisher: National Academy of Sciences
DOI: 10.1073/pnas.2103154118

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees

Author(s): Andreano, E. et al.
Published in: Nature Communications 13, 3375, Issue Nature Communications 13, 3375, 2022, ISSN 2041-1723
Publisher: Nature Publishing Group
DOI: 10.1038/s41467-022-31115-8

High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies

Author(s): Paciello, I., Maccari, G., Pantano, E., Andreano & Rappuoli, R
Published in: Proceedings of the National Academy of Sciences 121, e2314730121 (2024), Issue 121, e2314730121 (2024), 2024, ISSN 0027-8424
Publisher: National Academy of Sciences
DOI: 10.1073/pnas.2314730121

mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 and BA.5

Author(s): Emanuele Andreano, Ida Paciello, Giulio Pierleoni, Giuseppe Maccari, Giada Antonelli, Valentina Abbiento, Piero Pileri, Linda Benincasa, Ginevra Giglioli, Giulia Piccini, Concetta De Santi, Claudia Sala, Duccio Medini, Emanuele Montomoli, Piet Maes & Rino Rappuoli
Published in: Nature Communication, Issue (2023) 14:1734, 2023, ISSN 2041-1723
Publisher: Nature Publishing Group
DOI: 10.1038/s41467-023-37422-y

Non-peer reviewed articles (1)

Human monoclonal antibodies reveal subdominant gonococcal and meningococcal cross-protective antigens

Author(s): Troisi, M., et al.
Published in: COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv, Issue 2023.2012.2007.570438, 2023, ISSN 2692-8205
Publisher: bioRxiv
DOI: 10.1101/2023.12.07.570438